220 related articles for article (PubMed ID: 18156783)
41. Amplification of Duffy binding protein-encoding gene allows Plasmodium vivax to evade host anti-DBP humoral immunity.
Popovici J; Roesch C; Carias LL; Khim N; Kim S; Vantaux A; Mueller I; Chitnis CE; King CL; Witkowski B
Nat Commun; 2020 Feb; 11(1):953. PubMed ID: 32075983
[TBL] [Abstract][Full Text] [Related]
42. Sequence similarity between the erythrocyte binding domain of the Plasmodium vivax Duffy binding protein and the V3 loop of HIV-1 strain MN reveals a functional heparin binding motif involved in binding to the Duffy antigen receptor for chemokines.
Bolton MJ; Garry RF
Virol J; 2011 Nov; 8():523. PubMed ID: 22122911
[TBL] [Abstract][Full Text] [Related]
43. Development of quantitative receptor-ligand binding assay for use as a tool to estimate immune responses against Plasmodium vivax Duffy binding protein Region II.
Shakri AR; Rizvi MM; Chitnis CE
J Immunoassay Immunochem; 2012; 33(4):403-13. PubMed ID: 22963489
[TBL] [Abstract][Full Text] [Related]
44. Dynamics of asymptomatic Plasmodium vivax infections and Duffy binding protein polymorphisms in relation to parasitemia levels in Papua New Guinean children.
Cole-Tobian JL; Michon P; Dabod E; Mueller I; King CL
Am J Trop Med Hyg; 2007 Nov; 77(5):955-62. PubMed ID: 17984360
[TBL] [Abstract][Full Text] [Related]
45. Plasmodium vivax DBP binding to Aotus nancymaae erythrocytes is Duffy antigen dependent.
McHenry AM; Barnwell JW; Adams JH
J Parasitol; 2010 Feb; 96(1):225-7. PubMed ID: 19799492
[TBL] [Abstract][Full Text] [Related]
46. Protein PEGylation decreases observed target association rates via a dual blocking mechanism.
Kubetzko S; Sarkar CA; Plückthun A
Mol Pharmacol; 2005 Nov; 68(5):1439-54. PubMed ID: 16099846
[TBL] [Abstract][Full Text] [Related]
47. Mono and bivalent binding of a scFv and covalent diabody to murine laminin-1 using radioiodinated proteins and SPR measurements: effects on tissue retention in vivo.
Huang BC; Davern S; Kennel SJ
J Immunol Methods; 2006 Jun; 313(1-2):149-60. PubMed ID: 16750217
[TBL] [Abstract][Full Text] [Related]
48. Chapter 9 the duffy antigen receptor for chemokines.
Rot A; Horuk R
Methods Enzymol; 2009; 461():191-206. PubMed ID: 19480920
[TBL] [Abstract][Full Text] [Related]
49. Frequent expansion of Plasmodium vivax Duffy Binding Protein in Ethiopia and its epidemiological significance.
Lo E; Hostetler JB; Yewhalaw D; Pearson RD; Hamid MMA; Gunalan K; Kepple D; Ford A; Janies DA; Rayner JC; Miller LH; Yan G
PLoS Negl Trop Dis; 2019 Sep; 13(9):e0007222. PubMed ID: 31509523
[TBL] [Abstract][Full Text] [Related]
50. Expression, purification and characterization of a functional region of the Plasmodium vivax Duffy binding protein.
Dutta S; Daugherty JR; Ware LA; Lanar DE; Ockenhouse CF
Mol Biochem Parasitol; 2000 Jul; 109(2):179-84. PubMed ID: 10960177
[No Abstract] [Full Text] [Related]
51. Site-specific PEGylation of bone morphogenetic protein-2 cysteine analogues.
Hu J; Duppatla V; Harth S; Schmitz W; Sebald W
Bioconjug Chem; 2010 Oct; 21(10):1762-72. PubMed ID: 20886828
[TBL] [Abstract][Full Text] [Related]
52. Grafting of protein L-binding activity onto recombinant antibody fragments.
Muzard J; Adi-Bessalem S; Juste M; Laraba-Djebari F; Aubrey N; Billiald P
Anal Biochem; 2009 May; 388(2):331-8. PubMed ID: 19268418
[TBL] [Abstract][Full Text] [Related]
53. Mapping epitopes of the Plasmodium vivax Duffy binding protein with naturally acquired inhibitory antibodies.
Chootong P; Ntumngia FB; VanBuskirk KM; Xainli J; Cole-Tobian JL; Campbell CO; Fraser TS; King CL; Adams JH
Infect Immun; 2010 Mar; 78(3):1089-95. PubMed ID: 20008533
[TBL] [Abstract][Full Text] [Related]
54. Cloning antifungal single chain fragment variable antibodies by phage display and competitive panning elution.
Krishnaswamy S; Kabir ME; Miyamoto M; Furuichi Y; Komiyama T
Anal Biochem; 2009 Dec; 395(1):16-24. PubMed ID: 19665444
[TBL] [Abstract][Full Text] [Related]
55. Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand.
Albrecht H; Burke PA; Natarajan A; Xiong CY; Kalicinsky M; DeNardo GL; DeNardo SJ
Bioconjug Chem; 2004; 15(1):16-26. PubMed ID: 14733579
[TBL] [Abstract][Full Text] [Related]
56. Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility.
Albrecht H; Denardo GL; Denardo SJ
J Immunol Methods; 2006 Mar; 310(1-2):100-16. PubMed ID: 16499921
[TBL] [Abstract][Full Text] [Related]
57. A universal strategy for stable intracellular antibodies.
Shaki-Loewenstein S; Zfania R; Hyland S; Wels WS; Benhar I
J Immunol Methods; 2005 Aug; 303(1-2):19-39. PubMed ID: 16045924
[TBL] [Abstract][Full Text] [Related]
58. Sheep red blood cells armed with anti-CD20 single-chain variable fragments (scFvs) fused to a glycosylphosphatidylinositol (GPI) anchor: a strategy to target CD20-positive tumor cells.
Hamdy N; Goustin AS; Desaulniers JP; Li M; Chow CS; Al-Katib A
J Immunol Methods; 2005 Feb; 297(1-2):109-24. PubMed ID: 15777935
[TBL] [Abstract][Full Text] [Related]
59. The pattern of major polymorphisms in the Duffy binding protein ligand domain among Plasmodium vivax isolates from the Brazilian Amazon area.
Sousa TN; Cerávolo IP; Fernandes Fontes CJ; Couto A; Carvalho LH; Brito CF
Mol Biochem Parasitol; 2006 Apr; 146(2):251-4. PubMed ID: 16384615
[No Abstract] [Full Text] [Related]
60. Structure of an IgNAR-AMA1 complex: targeting a conserved hydrophobic cleft broadens malarial strain recognition.
Henderson KA; Streltsov VA; Coley AM; Dolezal O; Hudson PJ; Batchelor AH; Gupta A; Bai T; Murphy VJ; Anders RF; Foley M; Nuttall SD
Structure; 2007 Nov; 15(11):1452-66. PubMed ID: 17997971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
